|
An advisory panel to the FDA recommended new rAn advisory panel to the FDA recommended new restrictions for prescribing anemia drugs, including Johnson & Johnson's Procrit, after studies showed that high doses increased the risk of heart attacks, strokes and death. Johnson & Johnson shares fell $1.61, or 2.5 percent, as a result.
| ||||||